Quantitative analysis for Cibus, Inc. (CBUS) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (31.0) (grade D). 27 signals analyzed (23 differentiated alt-data).
CBUS stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $1.49 | $1.40 | $1.42 |
| 2026-05-08 | $1.53 | $1.43 | $1.44 |
| 2026-05-20 | $1.46 | $1.32 | $1.42 |
| 2026-06-02 | $1.49 | $1.39 | $1.39 |
| 2026-06-12 | $1.28 | $1.18 | $1.23 |
| 2026-06-25 | $1.45 | $1.33 | $1.34 |
| 2026-07-08 | $1.83 | $1.42 | $1.82 |
| 2026-07-20 | $1.84 | $1.73 | $1.76 |
| 2026-07-30 | $2.04 | $1.86 | $1.93 |
| 2026-08-12 | $1.95 | $1.84 | $1.89 |
| 2026-08-24 | $1.76 | $1.65 | $1.73 |
| 2026-09-03 | $1.60 | $1.53 | $1.58 |
How Cibus, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| XTNT | Xtant Medical Holdings, Inc. | $65M | — |
| INO | Inovio Pharmaceuticals, Inc. | $66M | — |
| SGMO | Sangamo Therapeutics, Inc. | $66M | — |
| GUTS | Fractyl Health, Inc. Common Stock | $67M | — |
View all Health Care stocks by valuation and signals →
Cibus, Inc. (CBUS) scores Sell (31.0), and the composite conceals a 84-point disagreement between its dimensions. It is strongest on competitive moat at 91 and analyst consensus at 66, and weakest on ML forecast at 21 and technicals at 7. A stock can carry competitive moat that high while technicals sits at 7; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 91 |
| analyst consensus | 66 |
| ML forecast | 21 |
| technicals | 7 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Cibus, Inc. (CBUS): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CBUS"><img src="https://stoquant.com/badge/CBUS.svg" alt="Cibus, Inc. (CBUS) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.